In a large cohort of patients with de novo mPDAC, more than half of patients were untreated or unable to tolerate CTx, possibly related to older age and worse PS, and this findings highlight a significant need for improved treatment options for mPDAC.
Abstract
Metastatic pancreatic adenocarcinoma (mPDAC) is associated with poor prognosis and limited treatment options. While guidelines recommend chemotherapy (CTx) for patients with good performance status (PS), many patients do not receive CTx or discontinue shortly after initiation. Non-treatment is often attributed to poor PS, comorbidities, or organ dysfunction; however, treatment-related factors including toxicity burden and limited effectiveness of available CTx options may also contribute. This study aimed to understand characteristics and outcomes of patients with de novo mPDAC who do not receive or are intolerant to CTx.
This study used ConcertAI Patient360™ electronic health records with linked claims. Adult patients were included if they were diagnosed with de novo mPDAC between 1/2020–3/2025 and had >3 months of follow-up unless censored due to death. Patients were categorized into 3 cohorts: CTx-untreated, CTx-tolerant (initiated and continued CTx for >90 days unless due to progression), and CTx-intolerant (initiated CTx within 90 days of diagnosis but discontinued within 90 days without evidence of progression or re-treatment). Demographics, clinical characteristics, overall survival (OS), and resource utilization were evaluated.
Of the 2708 patients meeting eligibility criteria, 953 (35%) were CTx-untreated. A total of 1635 initiated treatment within 90 days; 1105 (41%) were classified as CTx-tolerant and 530 (20%) as CTx-intolerant. CTx-untreated patients tended to be older and had worse PS. CTx-intolerant patients were slightly older and had worse PS than CTx-tolerant patients. Median OS was 1.74 months in CTx-untreated, 11.37 months in CTx-tolerant, and 2.63 months in CTx-intolerant patients. CTx-untreated and CTx-intolerant patients had higher resource utilization per patient per month.
In a large cohort of patients with de novo mPDAC, more than half of patients were untreated or unable to tolerate CTx, possibly related to older age and worse PS. Survival was substantially shorter and resource utilization higher in these groups than among those who received and tolerated CTx. While CTx demonstrates improved outcomes among those who receive and tolerate it, these findings also highlight a significant need for improved treatment options for mPDAC.
Shubham Pant, Pranoti Pradhan, Yuexi Wang, Aliza R. Karpes Matusevich, Ziyu Lan, Brandon Kent, Clay Gustafson, John Graham, Preeti S. Bajaj. Chemotherapy utilization and outcomes in patients with metastatic pancreatic adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr A137.
Pat, socioeconomic, and healthcare factors were associated with both non-receipt of cancer-directed treatment and reasons for non-treatment among patients with advanced GIC, suggesting that potentially modifiable healthcare access and care delivery factors may contribute substantially to treatment non-receipt.
M. Castañeda-Avila, Jonggyu Baek, Tasneem Ali et al.· Cancer Epidemiology, Biomark...· 0 citations
178
Background:
Delay in time from muscle invasive bladder cancer (MIBC) diagnosis to neoadjuvant chemotherapy (NACT) > 60 days, can negatively impact cancer related outcomes. However, the underlying causes of these delays remain poorly characterized, underscoring the need for further investigation.
Methods:...
Margaux Wooster, Abha Kulkarni, R. Raghunathan et al.· JCO Oncology Practice· 0 citations
BACKGROUND
With increasing detection of asymptomatic or limited metastatic esophagogastric adenocarcinoma (mEAC), deferring systemic therapy may spare patients toxicity and hospital visits, but its impact on overall survival (OS) and health-related quality of life (HRQoL) is unclear.
METHODS
Patients diagnosed with m...
D. Kamp, A. May, Rob Kessels et al.· European Journal of Cancer· 0 citations
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically significant neurotoxicity associated with taxane-based chemotherapy, which is frequently leading to treatment modification or discontinuation. In the neoadjuvant setting, treatment-limiting CIPN may compromise the delivery of planne...
R. Negreanu, N. Verga, Raluca Elena Negreanu· Maedica· 0 citations
In a population where few had received treatment intensification for metastatic hormone-sensitive prostate cancer, real-world outcomes were aligned with those observed previously and in clinical trials, however, there remains significant need to broaden access to effective systemic therapy in mCRPC and to find new trea...
Robert J. Jones, Katherine Houghton, A. Niyazov et al.· Cancer Treatment and Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.